StockUS listing USRSPIPINKHealthcareCapital Destroyer

RespireRx Pharmaceuticals Inc(RSPI) Stock Analysis | Healthcare

USD --+0.00%
Reward31Low
Risk66Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 849134
Reward Ratingⓘ31 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ66 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RSPI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is RespireRx Pharmaceuticals Inc?

engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders.

AI Brief Pro

The brief on RespireRx Pharmaceuticals Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is RespireRx Pharmaceuticals Inc?

engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 849.13K.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (31)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap849.13K
Beta0.606
Insider Activity
12M windowNo data
No insider activity data available for this ticker.